Table 1.

Characteristics of included SRs.

Included study	Country	Age	Included study design	No. of study	No. of patient	Intervention	Comparator	Outcomes	Assessment of methodological quality	Meta-analysis conducted?	Subgroup	Sensitivity	Safety
Li [24] (2009)	China	Age ≥ 12 years old	RCT	12	984	Acupuncture therapy or combined with conventional medicine	Conventional medicine	(2) (3) (6)	Classified by the Cochrane handbook. The version is not stated and the Jadad scale evaluation	Yes	Yes	No	Yes
Yan [19] (2015)	China	Any age	RCT	8	755	Any acupoint stimulation or combined with other therapy	No treatment/placebo or western medication; same other therapy	(1) (8)	Classified by the Cochrane handbook. The version is not stated	Yes	Yes	No	Yes
Yao [22] (2016)	China	Any age	RCT	6	406	Acupuncture or combined with another active therapy	No treatment/placebo/sham acupuncture/other same active therapies	(1) (2) (3) (9)	Classified by the Cochrane handbook. The version is not stated	Yes	No	No	Yes
Liang [41] (2016)	China	Any age	RCT	15	1554	Autohemotherapy or combined with an antihistamine or other treatment	Antihistamine or acupuncture	(1) (2) (3) (7)	Classified by the Cochrane handbook. The version is not stated	Yes	Yes	No	Yes
Chen [33] (2016)	China	Any age	RCT	5	545	Autohemotherapy	Other therapies except for Autohemotherapy	(4)	Classified by the Cochrane handbook. The version is not stated	Yes	No	No	No
An [38] (2016)	China	Any age	RCT	12	988	Autohemotherapy	Other therapies except for autohemotherapy	(1) (3)	Jadad scale evaluation	Yes	Yes	Yes	No
Luo [39] (2016)	China	Any age	RCT	8	937	Autohemotherapy or combined with other therapies	Other therapies	(1) (3) (4)	Cochrane 5.0.1 and Jadad scale evaluation	Yes	Yes	Yes	Yes
Liu [35] (2017)	China	Any age	RCT/CCT	6	515	Autohemotherapy	Conventional western therapy	(4)	Jadad scale evaluation	Yes	No	No	No
Pu [28] (2017)	China	Any age	RCT	10	686	Autohemotherapy or combined with antihistamines	Antihistamine or acupuncture therapy	(2) (3) (4)	Cochrane 5.0.1	Yes	No	No	Yes
Zhang [31] (2018)	China	Any age	RCT	9	751	Acupoint embedding or combined with other therapies	Other therapies except for acupoint embedding	(1) (5) (6)	Classified by the Cochrane handbook. The version is not stated	Yes	No	Yes	Yes
Liang [32] (2018)	China	Any age	RCT/quasi-RCT/CCT	7	528	Acupoint embedding or combined with other therapies	Other therapies except for acupoint embedding	(4) (6)	Jadad scale evaluation	Yes	No	Yes	No
Zhu [21] (2018)	China	Any age	RCT	7	624	Auriculotherapy or combined with other therapies	Western medicine	(2) (4) (10)	Cochrane 5.0.1	Yes	No	Yes	Yes
Li [37] (2018)	China	Any age	RCT	14	1051	Autohemotherapy or combined with other therapies	Other therapies except for autohemotherapy	(1) (3) (6)	Classified by the Cochrane handbook. The version is not stated	Yes	No	Yes	Yes
Wei [26] (2019)	China	Any age	RCT	12	836	Acupoint embedding	Other therapies except for acupoint embedding	(2) (3) (4) (6)	Classified by the Cochrane handbook. The version is not stated	Yes	No	Yes	Yes
Zhao [40] (2019)	China	Age ≥ 18 years old	RCT	16	1131	Acupuncture/electroacupuncture (can be moxibustion, cupping, bleeding, etc.) or combined with the same intervention measures as the control group	Western medicine	(1) (3) (6) (7) (10)	Classified by the Cochrane handbook. The version is not stated	Yes	Yes	Yes	Yes
Li [36] (2019)	China	Any age	RCT	11	763	Autohemotherapy combined with other therapies	Other therapies except for autohemotherapy	(3) (6)	Classified by the Cochrane handbook. The version is not stated	Yes	No	No	Yes
Wu [29] (2019)	China	Any age	RCT	13	1608	Autohemotherapy combined with H1 receptor antagonists	H1 receptor antagonists	(1) (2) (3)	Cochrane 5.0.1	Yes	Yes	Yes	Yes
Zhao [30] (2019)	China	Any age	RCT/CCT	12	944	Autohemotherapy combined with acupuncture and other therapies	Other therapies except for autohemotherapy	(1) (2) (3) (4)	Cochrane 5.1.0 and Jadad scale evaluation	Yes	Yes	Yes	Yes
Yao [20] (2019)	China	Any age	RCT	7	512	Bloodletting therapy or combined with other active therapies	No treatment/placebo/sham bloodletting therapy/other same active therapies	(1) (2) (11)	Classified by the Cochrane handbook. The version is not stated	Yes	No	Yes	Yes
Zhao [27] (2020)	China	Age ≥ 18 years old	RCT	16	1131	Acupuncture or combined with western medicine	Western medicine	(1) (3) (10)	Classified by the Cochrane handbook. The version is not stated	Yes	No	Yes	No
Zhang [34] (2020)	China	Any age	RCT/quasi-RCT	16	1325	Acupuncture	Western medicine	(1) (3) (6)	Jadad scale evaluation	Yes	No	No	No
Xiao [23] (2020)	China	Any age	RCT	12	842	Dry/wet cupping or combination with other therapies	Other therapies	(1) (2) (3) (8)	Cochrane 5.0.1	Yes	Yes	No	Yes
Ke [25] (2021)	China	Any age	RCT	7	510	Acupuncture therapy combined with herbal decoction	Antihistamine	(1) (3) (4)	Classified by the Cochrane handbook. The version is not stated	Yes	No	Yes	Yes

Note. Outcomes: (1) total efficiency: according to the severity of clinical symptoms using 4 scores; the total score is the sum of the individual scores. Symptom Score Reducing Index (SSRI)=(total score before treatment-total score after treatment)/total score before treatment×100%; (2) adverse reaction rate; (3) recurrence rate; (4) clinical efficacy rate: the clinical complete recovery is considered to be effective, others are invalid; (5) improvement rate; (6) curing rate; (7) IgE levels; (8) the Dermatology Quality Life Index (DLQI); (9) quality of life score (QoL); (10) total improvement of clinical signs and symptoms; (11) disease activity control.